StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) from a sell rating to a hold rating in a report released on Friday morning.
Several other brokerages have also recently issued reports on ANIP. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday. They issued a "buy" rating and a $80.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $79.75.
Check Out Our Latest Stock Report on ANIP
ANI Pharmaceuticals Price Performance
Shares of ANIP stock traded up $1.86 during midday trading on Friday, reaching $64.35. 334,305 shares of the company traded hands, compared to its average volume of 238,112. The firm's 50 day simple moving average is $58.59 and its two-hundred day simple moving average is $58.07. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market cap of $1.40 billion, a PE ratio of -117.00 and a beta of 0.63.
Insider Activity at ANI Pharmaceuticals
In related news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,700 shares of company stock valued at $610,201. Company insiders own 12.70% of the company's stock.
Institutional Investors Weigh In On ANI Pharmaceuticals
Several hedge funds have recently modified their holdings of ANIP. JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Thompson Siegel & Walmsley LLC lifted its stake in shares of ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after purchasing an additional 34,416 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Mizuho Markets Americas LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $11,670,000. 76.05% of the stock is owned by institutional investors and hedge funds.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
